Possible Impact of 190G > A CCR2 and Δ32 CCR5 Mutations on Decrease of the HBV Vaccine Immunogenicity-A Preliminary Report

• Published in: International journal of environmental research and public health 2017-02, Vol.14 (2), p.166
• Main Authors: Ganczak, Maria, Skonieczna-Żydecka, Karolina, Drozd-Dąbrowska, Marzena, Adler, Grażyna
• Format: Article
• Language: English
• Subjects: Adult; Body mass index; CCR2 protein; CCR5 protein; Chemokines; Demographics; Disease; Enzyme-Linked Immunosorbent Assay; Enzymes; Female; Gender; Gene expression; Gene frequency; Gene polymorphism; Genetic diversity; Genetic Variation; Genotype; Genotype & phenotype; Genotypes; Health care; Hepatitis B; Hepatitis B Antibodies - immunology; Hepatitis B Vaccines - immunology; Homozygotes; Human papillomavirus; Humans; Immunogenicity; Immunogenicity, Vaccine - genetics; Infections; Infectious diseases; Male; Middle Aged; Monocyte chemoattractant protein 1; Mutation; Nucleotides; Poland; Polymerase Chain Reaction; Polymorphism; Polymorphism, Genetic; Primary care; Public health; Receptors, CCR5 - genetics; Serologic Tests; Single-nucleotide polymorphism; Statistical analysis; Vaccination; Vaccines; Viral infections; Viruses; West Nile virus
• ISSN: 1660-4601; 1661-7827; 1660-4601
• DOI: 10.3390/ijerph14020166

: Chemokine genetic variations are involved in infectious diseases such as hepatitis B virus (HBV). Several allelic variants might, in theory, affect the outcome of vaccination. : This study was carried out to examine the associations of Δ32 and 190G > A polymorphisms with a response to a primary course of three HBV vaccinations. : Between December 2014 and December 2016, patients from three randomly selected primary care clinics in the West Pomeranian region (Poland), 1 month after receiving the third dose of HBV vaccine, were enrolled. Enzyme-linked immunosorbent assay (ELISA) system version 3.0 was used to detect anti-HBs and anti-HBc totals. The identification of polymorphisms were performed by a polymerase chain reaction technique using a single primer extension assay. Genotype distributions of responders versus non-responders to HBV vaccination were compared on the basis of anti-HBs level. : In 149 patients (mean age 60 years) the mean anti-HBs level was 652.2 ± 425.9 mIU/mL (range: 0-1111.0 mIU/mL). There were 14.1% ( = 21) non-responders to the HBV vaccine (anti-HBs < 10.0 mIU/mL). The wild type/Δ32 genotype of gene was found in 18.1% participants, and 1.3% were Δ32/Δ32 homozygotes. The frequency of allele A of the gene was 11.1%. Lower anti-HBs levels in Δ32/Δ32 homozygotes were observed (Me = 61 mIU/mL vs. Me = 660.2 mIU/mL; = 0.048). As age was found to be a correlate to the anti-HBs titer ( = -0.218, = 0.0075; 95% CI: -0.366--0.059)-an analysis of a co-variance was performed which found a statistically significant ( = 0.04) difference in anti-HBs titres between Δ32/Δ32 homozygotes and other genotypes. The association between anti-HBs titres and genotypes was not statistically significant. : Our study-which is a preliminary report that suggest this topic deserves further observation with larger sample sizes, different ethnicities, and other single nucleotide poly-morphisms (SNPs)-suggests the possible involvement of polymorphism in impairing the immunologic response to HBV vaccination, predominantly in relation to the passage of time.